Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Growth Hormone Secretagogue Receptor Type 1, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Secretagogue Receptor Type 1 and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Growth Hormone Secretagogue Receptor Type 1 Overview
  3. Therapeutics Development
  4. Pipeline Products for Growth Hormone Secretagogue Receptor Type 1 - Overview
  5. Pipeline Products for Growth Hormone Secretagogue Receptor Type 1 - Comparative Analysis
  6. Growth Hormone Secretagogue Receptor Type 1 - Therapeutics under Development by Companies
  7. Growth Hormone Secretagogue Receptor Type 1 - Therapeutics under Investigation by Universities/Institutes
  8. Growth Hormone Secretagogue Receptor Type 1 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Growth Hormone Secretagogue Receptor Type 1 - Products under Development by Companies
  13. Growth Hormone Secretagogue Receptor Type 1 - Products under Investigation by Universities/Institutes
  14. Growth Hormone Secretagogue Receptor Type 1 - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Aeterna Zentaris Inc.
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Alize Pharma SAS
  • Helsinn Healthcare S.A.
  • Pfizer Inc.
  • RaQualia Pharma Inc.
  • Rhythm Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/qxj9jm/growth_hormone

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Endocrine and Metabolic Disorder Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Endocrine and Metabolic Disorder Drugs